La chaîne d'options affiche les données clés des options sur actions de Amylyx Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Amylyx Pharmaceuticals..

Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock, Chaîne d'Options

AMYLYX PHARMACEUTICALS INC

Amylyx Pharma

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals Inc

Biotech

News

Health Care

General

PHIO

Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1b Clinical Trial Of Intratumoral PH-762 In The Treatment Of Stages 1, 2, And 4 Cutaneous Squamous Cell Carcinoma, Stage 4 Melanoma, And Stage 4 Merkel Cell Carcinoma

BCRX

FDA Extends PDUFA Date To December 12, 2025 For BioCryst ORLADEYO NDA In Pediatric HAE After Major Amendment Submission

Politics

Global

Beijing Asks Rare-Earth Firms For Information About Their Experts;  Aims To Keep Tabs On Experts, Prevent Trade-Secret Leaks

Earnings

DAKT

Daktronics Says Business And Digital Transformation On Track; Reconfirms Three Year Forward Objectives Of 7%-10% Sales Growth, 10%-12% Operating Margin, 17%-20% ROIC

Daktronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAKT#NASDAQ">DAKT</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.15 by 17.65 percent. This is a 33.33 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $172.55 million which missed the analyst consensus estimate of $193.96 million by 11.04 percent. This is a 20.07 percent decrease over sales of $215.88 million the same period last year.

Earnings Beats

Earnings Misses

Daktronics Q4 Adj. EPS $0.18 Beats $0.15 Estimate, Sales $172.55M Miss $193.96M Estimate

Crypto markets are holding steady, boosted by growing optimism over a potential Federal Reserve rate cut, <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46068856/peter-schiff-slams-texas-for-authorizing-bitcoin-reserve-another-example-of-why-the-founding-fathers-distrusted-democracy">Arizona's new Bitcoin reserve law</a>, and continued institutional accumulation. 
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$107,127.27</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,426.90</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$145.86</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.19</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1653</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001162</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction volume increasing by 9% and 12%, respectively. Daily active addresses are up by 12% and 19.6%, respectively.</li>
<li>Coinglass data shows 76,197 traders were liquidated in the past 24 hours for $169.71 million.</li>
<li>SoSoValue data shows net inflows of $588.6 million into spot Bitcoin ETFs on Tuesday, while spot Ethereum ETFs saw net inflows of $71.2 million.</li>
</ul>
Trader Notes: Crypto trader Jelle highlighted Bitcoin's quick recovery after briefly dipping below recent lows. The reclaim of a key resistance level suggests strength, with liquidity clusters just overhead, potentially setting up for a rapid upside move..
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> took out the lows, and immediately reclaimed the key resistance level, and now pushes higher. Bunch of liquidity sitting just overhead. This could get interesting. <a href="https://t.co/Gx3txfZmjB">pic.twitter.com/Gx3txfZmjB</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1937803616263229705?ref_src=twsrc%5Etfw">June 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
On the other hand, Rekt Capital <a href="https://x.com/rektcapital/status/1937826121334309111">noted</a> Bitcoin is now positioned to break out of its multi-week downtrend. But to confirm a reversal, Bitcoin must close the week solidly above a key diagonal trendline, not just wick above it.
Ted Pillows <a href="https://x.com/TedPillows/status/1937816790354329876">pointed</a> out that Ethereum is currently holding the range low but must reclaim $2,525 to resume upward momentum toward the range highs.
Ameba <a href="https://x.com/Ameba_NM/status/1937768205960802625">observed</a> that Solana's reclaim of the MH level could lead to a short-term surge toward the monthly open. A breakout above that would likely bring strong bullish momentum.
Trader Tardigrade <a href="https://x.com/TATrader_Alan/status/1937798438407835893">emphasized</a> that Dogecoin continues to respect a long-term weekly support trendline that&#8217;s held for over 18 months, suggesting the meme coin remains technically sound.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46080751/anthony-pomplianos-procap-buys-over-3700-bitcoin-whats-driving-the-aggressive-bet">Anthony Pompliano&#8217;s ProCap Buys Over 3,700 Bitcoin—What&#8217;s Driving The Aggressive Bet?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Hold Gains As Crypto ETF Inflows Continue

Sonder Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOND#NASDAQ">SOND</a>) ("Sonder" or the "Company") today announced that after a transformative tenure as Co-Founder and Chief Executive Officer, Francis Davidson has stepped down as Sonder's Chief Executive Officer and as a member of the Company's Board of Directors. Janice Sears, Sonder's Chairperson of the Board, has been appointed Interim Chief Executive Officer, effective immediately. Ms. Sears will continue to serve as Sonder's Board Chairperson. The Board intends to immediately initiate a search process to identify Sonder's next CEO.
 &nbsp;

Management

SOND

Sonder Holdings CEO Francis Davidson Steps Down; Board Chair Janice Sears Named Interim CEO, Effective Immediately

<ul>
<li>Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)</li>
<li>Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersen</li>
<li>Based on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA &nbsp;</li>
</ul>
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=mqiGWYMuKfEonBYy6qMH-_1QrPITPn3OfJOt0ipADJSKUxY8-i9HvsJlmdCbsNsl39Ta1psj5YPS_0RxQ_acvg==">Biogen</a> Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for the treatment&nbsp;of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and enable once yearly dosing. An interim analysis of the Phase 1 study in participants with SMA who were previously treated with gene therapy was conducted to inform the decision on whether to move salanersen forward into registrational studies. Both dose levels tested, 40 mg and 80 mg, given once a year, were generally well-tolerated and led to substantial slowing of neurodegeneration, as shown by reductions in neurofilament. Exploratory clinical outcome data shows clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over 1 year. These data will be presented today at the SMA Research &amp; Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif.

BIIB

Biogen Announces Topline Results From Phase 1 Study Of Salanersen, Antisense Oligonucleotide Being Developed For Treatment Of Spinal Muscular Atrophy

Reflecting the surging tide of artificial intelligence, Wedbush Securities analyst Dan Ives has raised his price target for Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) to $600, up from an earlier estimate of $425, citing a &#8220;massive adoption wave&#8221; of AI-driven Azure services.
What Happened: The announcement, made via X, underscores Ives&#8217; confidence in Microsoft's pivotal role in the AI revolution, dubbing it the company's &#8220;shining moment.&#8221;
The new target implies a 23% upside for Microsoft investors based on Tuesday's closing price.
Ives, a veteran tech bull on Wall Street, bases his bullish outlook on recent field checks revealing robust AI customer adoption.
Microsoft's Azure cloud platform, enhanced by innovations like Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/markets/equities/25/05/45510847/jensen-huang-satya-nadella-tout-40x-speed-up-in-azure-powered-ai-as-microsoft-nvidia-deepen-supercomputing-alliance">Hopper GPUs and custom-built silicon</a>, is at the forefront, with monetization strategies outlined in the Azure API Management framework driving significant growth. 
The new target, approximately 25% premium over the current Wall Street consensus of $517.85, reflects Ives' belief that AI infrastructure is propelling Microsoft ahead of competitors.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Raising our price target on Microsoft to $600 reflecting incrementally bullish recent AI customer checks in the field with a massive adoption wave of AI driven Azure monetization now on the doorstep for MSFT. We strongly view this as Microsoft&#39;s &quot;shining moment&quot; with AI &#x1f3c6;&#x1f402;&#x1f525;&#x1f37f;
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1937820305348837882?ref_src=twsrc%5Etfw">June 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/46068345/blackrock-bets-big-on-defense-companies-amid-escalating-geopolitical-tensions-palantir-lockheed-martin-northrop-grumman-among-stocks-in-focus">BlackRock Bets Big On Defense Companies Amid Escalating Geopolitical Tensions: Palantir, Lockheed Martin, Northrop Grumman Among Stocks In Focus</a>
Why It Matters: Currently, based on the <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">29 analysts tracked by Benzinga</a>, MSFT has a consensus target price of $517.85 apiece, with a &#8216;buy&#8217; rating.
The targets range from $475 to $605. Recent price targets from Wells Fargo, Citigroup, and RBC Capital imply a 15.07% upside for Microsoft Corp.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="385" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065238/MSFT-ANR-new-1024x385.png" alt="" class="wp-image-961398" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065238/MSFT-ANR-new-1024x385.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065238/MSFT-ANR-new-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065238/MSFT-ANR-new-768x289.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065238/MSFT-ANR-new.png 1072w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
MSFT shares were up 0.22% in premarket on Wednesday and ended 0.85% higher at $490.11 apiece on Tuesday. It has risen by 17.09% on a year-to-date basis and 8.68% over the past year. 
Benzinga Edge Stock Rankings shows that MSFT had a stronger price trend over the short, medium, and long term. Its momentum ranking was solid; however, its value ranking was poor at the 13.32nd percentile. The details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="865" height="130" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065151/MSFT-EDGE.png" alt="" class="wp-image-961395" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065151/MSFT-EDGE.png 865w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065151/MSFT-EDGE-300x45.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065151/MSFT-EDGE-768x115.png 768w" sizes="(max-width: 865px) 100vw, 865px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Wednesday. The SPY was down 0.054% at $607.11, while the QQQ rose 0.16% to $540.66, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/25/06/46089173/michael-saylor-offers-btc-credit-model-as-bill-pulte-pushes-crypto-for-fannie-mae-freddie-mac-could-bitcoin-soon-count-toward-mortgage-qualification">Michael Saylor Offers BTC Credit Model As Bill Pulte Pushes Crypto For Fannie Mae, Freddie Mac: Could Bitcoin Soon Count Toward Mortgage Qualification?</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. 
Image via Shutterstock

MSFT

NVDA

Microsoft Stock Poised For 23% Rally As AI Monetization Gains Steam, Dan Ives Says

- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer's Disease Scheduled -
- Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies -
PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=KdsnSg5rcq4bA2J8hqBpQj8lWM9rgYhvZSWM125zklYwbZm_6JoBEOJUD2FOniY56qp67Xy19gTIn6KYIWxAyCPRQS_5gV-sW1-hmlNjqL5TQaXxGCUOix93YEGeGae5">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company will conduct an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on July 9, 2025. During the meeting, the Cognition team will review results of the Phase 2 'SHINE' study (<a href="https://www.globenewswire.com/Tracker?data=_MCpzuFFyrefjxZ9d-cZnmAO1MOxvxFHE4LkQnqVInCbPk2FtdhDRQ5HLjtXhUEv7g3xWF6na98ny1Z2eS4QZjXxm1kNgasp2Ix5JVSe0HyImfx1ext1iotjp9v-KO46">NCT03507790</a>) of zervimesine (CT1812) in mild-to-moderate Alzheimer's disease. In addition, proposed plans for a Phase 3 program designed to support regulatory approval of zervimesine in this patient population will be discussed with the FDA.
Breakthrough therapy designation is designed by the FDA to expedite the development and regulatory review of promising therapies for serious or life-threatening conditions where preliminary clinical evidence suggests substantial improvement over existing treatments. The designation facilitates more intensive FDA guidance, cross-disciplinary collaboration, and eligibility for rolling submission and priority review. The FDA typically reviews applications for breakthrough designation within 60 days.
The expanded access program (EAP) for zervimesine in DLB is progressing with high interest among former SHIMMER participants. The EAP is enrolling adults with DLB who participated in the SHIMMER study, as well as others who meet the program's eligibility criteria. While one site is currently open, the Cognition team is working closely with other sites to complete onboarding so that they may be open to patients soon.

CGTX

Cognition Therapeutics To Conduct End-Of-Phase 2 Meeting With FDA For Mild-To-Moderate Alzheimer's Disease On July 9, 2025

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fionis.com%2F&amp;esheet=54281950&amp;newsitemid=20250625591486&amp;lan=en-US&amp;anchor=Ionis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=170ceac2a025b1dbda3decf050844ab4">Ionis Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA&#xAE; (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and enable once-yearly dosing. Both dose levels tested, 40 mg and 80 mg, given once a year, were generally well-tolerated and led to substantial slowing of neurodegeneration, as shown by reductions in neurofilament. Exploratory clinical outcome data show clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over one year. These data will be presented today at the SMA Research &amp; Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif.
The Phase 1 single ascending dose study was designed to evaluate the safety, tolerability and pharmacokinetics of salanersen. The trial consisted of two parts: Part A, a randomized and placebo-controlled segment in healthy adult male volunteers and Part B, an open-label segment in pediatric participants with SMA who previously received ZOLGENSMA&#xAE; (onasemnogene abeparvovec) and had investigator-reported suboptimal clinical status. Interim results are from Part B (n=24) in individuals who received either 40 mg or 80 mg salanersen once a year. In participants with elevated baseline concentrations of neurofilament light chain (NfL), indicating ongoing neurodegeneration, initiation of salanersen led to mean reductions in NfL of 70% at 6-months which were sustained through the one-year dosing interval.

IONS

Ionis and Biogen Report Early Success With Once-Yearly SMA Treatment Showing Strong Safety and Efficacy Signals

ABUS

Arbutus Reacquires Greater China Rights To Imdusiran From Qilu, Forms Scientific Advisory Board Focused On Late-Stage Hepatitis B Trials

JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) <a target="_blank" href="https://www.benzinga.com/topic/jd-com" rel="noreferrer noopener">has begun recruiting</a> full-time meal delivery riders through JD Logistics, stepping up its competition with Meituan (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MPNGY#OTC">MPNGY</a>) and Alibaba Group Holding&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) in China&#8217;s food delivery space.
The company launched hiring efforts to expand its workforce for its food delivery arm, JD Food Delivery, which now handles over 25 million orders daily, SCMP <a href="https://www.scmp.com/tech/big-tech/article/3315760/jdcom-hires-full-time-food-delivery-riders-challenge-meituan-alibaba?module=perpetual_scroll_0&amp;pgtype=article" target="_blank" rel="noreferrer noopener">reported</a> on Wednesday.
JD.com has primarily relied on its on-demand delivery unit, Dada Nexus, with 1.3 million active riders annually, to support this service.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45770679/alibaba-jd-see-sales-soar-in-618-festival-apple-and-xiaomi-emerge-as-top-selling-brands" rel="noreferrer noopener">Alibaba, JD See Sales Soar In 618 Festival, Apple And Xiaomi Emerge As Top Selling Brands</a>
According to CEO Sandy Xu Ran, as of mid-June, JD.com had hired more than 120,000 full-time riders and aims to reach 150,000 by the quarter&#8217;s end. Still, its rider count remains far below Meituan&#8217;s 7.45 million and Alibaba&#8217;s Ele.me with about 4 million.
Analyst Cheng Liteng told SCMP that JD.com&#8217;s use of full-time riders could improve service quality and reliability. However, he warned that managing an extensive in-house fleet could raise costs and strain profit margins unless the company improves efficiency.
The online food delivery market in China, valued at an estimated $81.9 billion in 2024 and <a href="https://www.imarcgroup.com/china-online-food-delivery-market">projected to soar</a> to $197.9 billion by 2033 (a CAGR of 9.79% from 2025-2033), is witnessing an escalating battle for supremacy among its major players. 
This robust growth is fueled by increasing internet penetration, a growing consumer demand for convenience, diverse culinary options, aggressive marketing tactics, and the incorporation of advanced technologies like artificial intelligence.
Meituan currently dominates this fiercely competitive arena, holding a commanding 70% market share with its daily orders reportedly reaching 90 million. However, rivals are making strategic moves to gain ground. 
This week, Alibaba demonstrated its intent by merging its food delivery platform Ele.me and its online travel agency Fliggy directly into its <a href="https://www.benzinga.com/markets/asia/25/06/46047699/alibaba-integrates-ele-me-and-fliggy-into-core-business-to-battle-rivals-in-delivery-war">core e-commerce business</a>, a move aimed at creating a more unified and streamlined user experience. 
Alibaba has also announced a significant milestone, with its daily quick commerce orders reaching 60 million. Meanwhile, JD.com&#8217;s food delivery service, a more recent entrant, has already achieved 25 million daily orders in early June.
Price Action:&nbsp;JD shares are trading higher by&nbsp;1.41% to&nbsp;33.04 premarket at&nbsp;last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45611836/chinas-food-delivery-war-turns-bloody-as-meituan-and-jdcom-lose-100-billion-in-market-value">Meituan And JD Shares Have Bled $100 Billion In Market Value Since Late 2024 — China&#8217;s Food Delivery Wars Are Thinning Out Its Tech Giants</a></li>
</ul>
Photo by Freer via Shutterstock

Asia

Tech

Media

BABA

MPNGY

China's Food Delivery War Heats Up As JD.com Recruits Thousands Of Full-Time Riders

WIIM

PSTV

Plus Therapeutics shares are trading higher after the company announced FDA clearance of its investigational new drug application for REYOBIQ to treat childhood brain cancer.

<ul>
<li>Provides enterprise AI teams access to GenAI model and serving layer in addition to Rubrik's ready-to-use, secure and governed data lake</li>
<li>Turbocharges model accuracy, while reducing inference time and lowering cost by up to 80%</li>
<li>Enhances Rubrik's leading engineering talent with Predibase's team. Founders are highly respected Google and Uber AI team alumni, who created the open source LoRA eXchange project.</li>
</ul>
Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) announced it has entered into an agreement to acquire Predibase to accelerate agentic AI adoption from pilot to production at scale. Together, Predibase and Rubrik will deliver radical simplicity in models and data, resulting in improved accuracy, lower costs, better performance, and automated data governance. Venture firms Greylock and Felicis led funding of Predibase to date; terms of the transaction were not disclosed. Completion of the transaction is subject to customary closing conditions.

RBRK

Rubrik To Acquire Predibase To Accelerate Agentic AI Adoption From Pilot To Production At Scale; Terms Undisclosed

Plus Therapeutics Announces FDA Clearance Of Investigational New Drug Application Using REYOBIQ In Childhood Brain Cancer

The most oversold stocks in the financial sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 3</a>0, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">LPL Financial Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>)</h3>
<ul class="wp-block-list">
<li>On June 23, LPL Financial, a wholly owned subsidiary of LPL Financial Holdings, released its monthly activity report for May 2025. The company's stock fell around 7% over the past month and has a 52-week low of $187.19.</li>
<li>RSI Value: 28.5</li>
<li>LPLA Price Action: Shares of LPL Financial fell 5.4% to close at $354.10 on Tuesday.</li>
<li>Edge Stock Ratings: 77.97 Momentum score with Value at 27.12. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/LPLA"><img loading="lazy" decoding="async" width="438" height="176" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25070616/image-375.png" alt="" class="wp-image-961427" style="width:329px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25070616/image-375.png 438w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25070616/image-375-300x121.png 300w" sizes="(max-width: 438px) 100vw, 438px" /></a></figure>
<h3 class="wp-block-heading">Affinity Bancshares Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFBI#NASDAQ">AFBI</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On March 7, Affinity Bancshares announced a stock repurchase program. The company's stock fell around 15% over the past six months and<a href="https://www.benzinga.com/quote/AFBI"> has a 52-week low</a> of $17.00.</li>
<li>RSI Value: 24.4</li>
<li>AFBI Price Action: Shares of Affinity Bancshares closed at $18.50 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625">AFBI stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625"><img loading="lazy" decoding="async" width="923" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25070717/image-376.png" alt="" class="wp-image-961431" style="width:665px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25070717/image-376.png 923w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25070717/image-376-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25070717/image-376-768x701.png 768w" sizes="(max-width: 923px) 100vw, 923px" /></a></figure>
<h3 class="wp-block-heading">Landmark Bancorp Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LARK#NASDAQ">LARK</a>)</h3>
<ul class="wp-block-list">
<li>On April 30, Landmark Bancorp posted first-quarter EPS of 81 cents, up from 49 cents a year ago. Abby Wendel, President and Chief Executive Officer of Landmark, commented, &#8220;I am pleased to report strong growth in net income this quarter driven by growth in net interest income, lower expenses and excellent credit quality. We continued to experience solid loan demand in the first quarter 2025, especially for commercial real estate and residential mortgage loans.&#8221; The company's stock fell around 16% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/LARK">low of $17.86</a>.</li>
<li>RSI Value: 21.9</li>
<li>LARK Ltd Price Action: Shares of Landmark Bancorp gained 0.4% to close at $24.13 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625">LARK shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625"><img loading="lazy" decoding="async" width="887" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25070844/image-377.png" alt="" class="wp-image-961433" style="width:569px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25070844/image-377.png 887w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25070844/image-377-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25070844/image-377-768x719.png 768w" sizes="(max-width: 887px) 100vw, 887px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

AFBI

LARK

LPLA

Top 3 Financial Stocks That May Explode This Month

Mark Rutte, the NATO Secretary-General, has extended his appreciation to President Donald Trump for his significant contribution to the escalation of European defense spending.
What Happened:&nbsp;&nbsp;Rutte&#8217;s message to Trump, which was shared on the president&#8217;s social media platform, Truth Social, commended Trump for driving Europe to a pivotal point in terms of defense spending. Rutte acknowledged Trump&#8217;s demand for all NATO allies to raise defense spending to 5% of their GDP, a move that has been met with controversy, particularly from Spain.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25071906/Screenshot-2025-06-25-at-4.48.54%E2%80%AFPM-638x1024.png" alt="" class="wp-image-961437" /></figure>
"It was not easy but we've got them all signed onto 5 per cent!" Rutte wrote. "Europe is going to pay in a BIG way, as they should, and it will be your win."
Despite the ongoing dispute, Rutte congratulated Trump for getting all allies, except Spain, to commit to the 5% target. This praise comes in the wake of Trump&#8217;s criticism of Spain&#8217;s opposition to the 5% demand, which he labeled as &#8220;very unfair to the rest&nbsp;of the people&#8221; while talking to reporters on Air Force One on his way to NATO. 
However, Spain&#8217;s reluctance to commit to the 5% target has stirred up controversy and heightened&nbsp;the likelihood of a clash&nbsp;at the forthcoming NATO summit. Despite this, Rutte reassured allies that Trump would not retract U.S. guarantees as long as they significantly ramped up their defense spending, <a href="https://www.ft.com/content/ce9eb7e4-7989-45f6-a3b3-3cdec73a8540">reported </a>The Financial Times. 
To address Trump's demands, Rutte has put forward a plan for allies to dedicate 3.5% of their GDP to core military spending and an additional 1.5% to areas like cyber capabilities and infrastructure by 2035.
See Also:&nbsp;<a href="https://benzinga.com/pressreleases/24/10/ab41310379/claritycheck-launches-innovative-reverse-lookup-tool-to-empower-users-against-digital-scams" target="_blank" rel="noreferrer noopener">ClarityCheck Launches Innovative Reverse Lookup Tool to Empower Users Against Digital Scams &#8211; Benzinga</a>
Why It Matters: The push for increased defense spending in Europe comes at a time when global defense budgets have reached unprecedented levels. According to a report by the&nbsp;Stockholm International Peace Research Institute (SIPRI), <a href="https://www.benzinga.com/25/04/45032800/global-defense-budgets-surge-to-27-trillion-as-europe-and-middle-east-lead-steepest-increase-since-cold-war-report">military expenditure </a>rose by 9.4% to $2.72 trillion in 2024, marking the most significant annual increase since the Cold War.
This demand for increased defense spending has also led to diplomatic tensions, as seen in the recent cancellation of a key security summit between the U.S. and Japan. Tokyo canceled the meeting after the Trump administration raised its demand for Japan to increase defense spending to 3.5% of GDP, up from the previously requested 3%.
Despite the controversy, NATO is actively seeking partnerships with the private sector to develop emerging and disruptive technologies, such as AI systems, to maintain its technological dominance over its adversaries.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/politics/25/06/46087132/elizabeth-warren-says-the-tax-break-for-mark-zuckerbergs-meta-is-so-bountiful-under-trumps-big-beau" target="_blank" rel="noreferrer noopener">Elizabeth Warren Says The Tax Break For Mark Zuckerberg&#8217;s Meta Is So Bountiful Under Trump&#8217;s &#8216;Big Beautiful Bill&#8217; That $35 Copay From Each American Won&#8217;t Still Match I</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Made 'Europe…Pay In A Big Way:' NATO Chief Lauds Role In Boosting Defense Spending

Superior Industries International, Inc. ("Superior" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>), one of the world's leading aluminum wheel suppliers, today announced that on June 24, 2025, it received a written notice from the New York Stock Exchange (the "NYSE") that the NYSE had determined to (A) immediately suspend trading in the Company's common stock, par value $0.01 per share (the "Common Stock"), due to a determination that the Company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000 pursuant to Section 802.01B of the NYSE Listed Company Manual, and (B) commence proceedings to delist the Common Stock.
The NYSE stated that it will apply to the Securities and Exchange Commission (the "SEC") to delist the Common Stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE's delisting determination. The Company does not intend to appeal the delisting determination.
Upon suspension of the trading of the Common Stock on NYSE, the Company expects that the Common Stock will trade publicly on the Pink Open Market operated by the OTC Markets Group, Inc. (commonly referred to as the "pink sheets") under the ticker symbol "SSUP" beginning on June 25, 2025.

Superior Industries Receives NYSE Delisting Notice After Market Cap Falls Below Threshold

QS: 42% &#x7C; <a href="https://www.benzinga.com//node/46083645">QuantumScape Achieves Key 2025 Milestone In The Scale-Up Of Its Production Capabilities With The Successful Integration Of Its Advanced Cobra Separator Process Into Baseline Cell Production</a>
&nbsp;
DTIL: 22% &#x7C; <a href="https://www.benzinga.com//node/46091286">Precision BioSciences shares are trading higher after the company received FDA Rare Pediatric Disease Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy.</a>
&nbsp;
FDX: -6% &#x7C; <a href="https://www.benzinga.com//node/46082829">FedEx shares are trading lower after the company reported Q4 financial results.</a>

Movers

DTIL

Market-Moving News for June 25th

Press Releases

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

Legal

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Comments

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals (AMLX) Options

Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL